StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > EXACT SCIENCES COMPLETES ACQUISITION OF THRIVE

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon Jan 05, 2021 3:50pm

185 Views

Post# 32226004

RE:RE:RE:EXACT SCIENCES COMPLETES ACQUISITION OF THRIVE

MarketMoney wrote:

LithLover wrote: Makes no sense that we would be sitting at a market cap of $44 million.

Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion.

InvestManOne wrote: EXACT SCIENCES COMPLETES ACQUISITION OF THRIVE EARLIER
DETECTION, CREATING A LEADER IN BLOOD-BASED, MULTI-CANCER SCREENING JAN 5, 2021

https://money.tmx.com/en/quote/EXAS:US/news/6819844710375101/Exact_Sciences_Completes_Acquisition_of_Thrive_Earlier_Detection_Creating_a_Leader_in_BloodBased_MultiCancer_Screening

look at Tesla market cap.....makes no sense? Remember the stock evaluation is based on actual demand and supply of the shares.....bid and ask........when a stock is in demand the valuation goes up no matter if they make money or not, no matter if they have debt or not, no matter if they have revenu or not...it's always at the end the demand and supply of the shares that determine the shareprice!!!

Exactly - this is all about investor sentiment and when it turns look out. Investors need to be convinced that Aristotle will be widely accepted and that means the US initially and then the world. We have a probable two year advantage over competitors here and need to take full advantage. Also, with the several millions we have for marketing, Aristotle will receive the send off that the failed Colonsentry should have had. Bottom line is that we need a lot of publicity and fanfare to get this moving so investors move in.